CA2926332A1 - Ubiquitinylated proteins - Google Patents

Ubiquitinylated proteins Download PDF

Info

Publication number
CA2926332A1
CA2926332A1 CA2926332A CA2926332A CA2926332A1 CA 2926332 A1 CA2926332 A1 CA 2926332A1 CA 2926332 A CA2926332 A CA 2926332A CA 2926332 A CA2926332 A CA 2926332A CA 2926332 A1 CA2926332 A1 CA 2926332A1
Authority
CA
Canada
Prior art keywords
cells
tumor
proteins
composition
ubiquitinylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2926332A
Other languages
English (en)
French (fr)
Inventor
Christopher TWITTY
Erik LESHANE
Bernard Fox
Hong-Ming Hu
Guangjie YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UBIVAC LLC
Providence Health and Services Oregon
Original Assignee
UBIVAC LLC
Providence Health and Services Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UBIVAC LLC, Providence Health and Services Oregon filed Critical UBIVAC LLC
Publication of CA2926332A1 publication Critical patent/CA2926332A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2926332A 2013-10-11 2014-10-10 Ubiquitinylated proteins Pending CA2926332A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361890054P 2013-10-11 2013-10-11
US61/890,054 2013-10-11
PCT/US2014/060180 WO2015054668A1 (en) 2013-10-11 2014-10-10 Ubiquitinylated proteins

Publications (1)

Publication Number Publication Date
CA2926332A1 true CA2926332A1 (en) 2015-04-16

Family

ID=52809877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2926332A Pending CA2926332A1 (en) 2013-10-11 2014-10-10 Ubiquitinylated proteins

Country Status (7)

Country Link
US (1) US10226518B2 (https=)
EP (1) EP3055322B1 (https=)
JP (1) JP6636915B2 (https=)
KR (1) KR20160127711A (https=)
CN (1) CN105934442B (https=)
CA (1) CA2926332A1 (https=)
WO (1) WO2015054668A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104877017A (zh) * 2015-05-06 2015-09-02 东南大学 一种抗肿瘤泛素化蛋白及其提取方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
WO2007058235A1 (ja) * 2005-11-17 2007-05-24 Medinet Co., Ltd. 融合蛋白質およびその薬学的用途
JP2012039877A (ja) * 2009-04-10 2012-03-01 Fukuoka Univ ユビキチン融合遺伝子およびそれを用いたｄｎａワクチン
EP2608811B1 (en) * 2010-08-27 2015-01-28 Providence Health & Services - Oregon Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates

Also Published As

Publication number Publication date
JP2016534042A (ja) 2016-11-04
EP3055322A4 (en) 2017-06-14
JP6636915B2 (ja) 2020-01-29
WO2015054668A1 (en) 2015-04-16
US20150104477A1 (en) 2015-04-16
US10226518B2 (en) 2019-03-12
CN105934442A (zh) 2016-09-07
CN105934442B (zh) 2020-03-06
EP3055322A1 (en) 2016-08-17
EP3055322B1 (en) 2019-09-25
KR20160127711A (ko) 2016-11-04

Similar Documents

Publication Publication Date Title
US12410392B2 (en) Delivery of biomolecules to immune cells
Harimoto et al. Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells
Speiser et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients
Jackaman et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
Yuan et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma
WO2020072700A1 (en) Hla single allele lines
Tirapu et al. Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens
EP3642331B1 (en) T-cell expansion method and uses
Shimizu et al. Vaccination with Antigen-Transfected, NKT Cell Ligand–Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells
Wada et al. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
Wang et al. Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway
CA2843200A1 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
Masuko et al. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
Oka et al. WT1 peptide vaccine as a paradigm for “cancer antigen-derived peptide”-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide
US10226518B2 (en) Ubiquitinylated proteins
CA3058284A1 (en) Methods to produce peptides, polypeptides or cells for modulating immunity
Engelstein et al. Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL
Schütz et al. MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
Ordaz et al. DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens
Twitty et al. Ubiquitinylated proteins
Seishima et al. Enhancing DC cancer vaccine by allogeneic MHC class II expression and Treg depletion
Blachere The role of heat shock proteins in antigen presentation by MHC class I molecules
Dennis et al. ABBS 2005, 38 (02): Evaluation of Antibody Responses Elicited by Immunization of Mice with a Pneumococcal Antigen Genetically Fused to Murine HSP70 and Murine Interleukin-4
Abu Identification of Glypican3-derived Long Peptides Capable of Inducing both CTL and Th cells and Useful for Immunotherapy of Hepatocellular Carcinoma
Moran Characterization of dendritic cells transduced with Venezuelan equine encephalitis virus replicon particles as therapeutic cancer vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190829

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107